Prot #R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Project: Research project

Project Details

StatusFinished
Effective start/end date2/25/209/28/21

Funding

  • ICON Clinical Research Limited (Prot #R2810-ONC-1788 // Prot #R2810-ONC-1788)
  • Regeneron Pharmaceuticals, Inc. (Prot #R2810-ONC-1788 // Prot #R2810-ONC-1788)